ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brand, P.L.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brand, P.L.P.
Eur Respir J 2001; 17:287-294
Copyright ©ERS Journals Ltd 2001


Inhaled corticosteroids reduce growth. Or do they?

P.L.P. Brand

Isala klinieken/Weezenlanden Hospital, PO Box 10500, 8000 GM, Zwolle, the Netherlands

CORRESPONDENCE: P.L.P. Brand, Isala klinieken/Weezenlanden Hospital, PO Box 10500, 8000 GM, Zwolle, the Netherlands. Fax: +31 38 4242734

Keywords: growth, inhaled corticosteroids, review

Received: May 20, 2000
Accepted October 18, 2000

Abstract

The class label warning in the United States for inhaled corticosteroids (ICS's) states that these drugs may reduce growth velocity in children. In this paper, the evidence for this warning is reviewed from a clinical point of view.

Children with asthma tend to grow slower than their healthy peers during the prepubertal years because they go into puberty at a later age. However, asthmatic children do achieve a (near) normal adult height. In randomized controlled clinical trials, the use of inhaled beclomethasone, budesonide and fluticasone is associated with a reduced growth during the first months of therapy, in the order of magnitude of approximately 0.5–1.5 cm·yr–1. It is, however, unlikely that such an effect continues or persists because accumulating evidence shows that asthmatic children, even when they have been treated with ICS for years, attain normal adult height. Individual rare cases have been reported, however, where ICS use was associated with clinically relevant growth suppression.

Inhaled corticosteroids are the most effective therapy available for maintenance treatment of childhood asthma. Fear of reduced growth velocity is based on exceptional cases and not on group data. It should, therefore, not be a reason to withhold or withdraw such highly effective treatment in children with asthma.




This article has been cited by other articles:


Home page
Eur Respir JHome page
M. Nuijsink, W. C. J. Hop, P. J. Sterk, E. J. Duiverman, J. C. de Jongste, and on behalf of the Children Asthma Therapy Optimal (
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial
Eur. Respir. J., September 1, 2007; 30(3): 457 - 466.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
M.J. Visser, E. van der Veer, D.S. Postma, L.R. Arends, T.W. de Vries, P.L.P. Brand, and E.J. Duiverman
Side-effects of fluticasone in asthmatic children: no effects after dose reduction
Eur. Respir. J., September 1, 2004; 24(3): 420 - 425.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the European Respiratory Society.